DRRX DURECT Corporation

-0.01  -1%
Previous Close 0.58
Open 0.57
Price To Book 4.77
Market Cap 92779189
Shares 162,059,718
Volume 273,048
Short Ratio
Av. Daily Volume 326,939

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced July 27, 2018.
Phase 2 commencement of dosing announced March 21, 2019 with top-line data due 2H 2019.
CRL issued February 12, 2014.
Post-operative pain relief
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Noted October 19, 2017 that primary endpoint was not met. Noted February 27, 2019 that it plans to resubmit its NDA 1H 2019.
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Phase 2 initial data due 2H 2019.
Nonalcoholic steatohepatitis (NASH)
Phase 2 90 mg cohort to be completed 2019.
Alcoholic hepatitis (AH)

Latest News

  1. DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH
  2. DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
  3. DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
  4. Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT
  5. DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year
  6. Durect Corp (DRRX) Files 10-K for the Fiscal Year Ended on December 31, 2018
  7. DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs
  8. DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call
  9. DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter
  10. DURECT Corporation (NASDAQ:DRRX): Time For A Financial Health Check
  11. Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth
  12. DURECT Corporation to Participate in the Berenberg NASH Day
  13. Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug
  14. DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications
  15. Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT
  16. DURECT Corporation Provides Corporate Update
  17. Here’s What We Think About DURECT Corporation’s (NASDAQ:DRRX) CEO Pay
  18. DURECT Corporation Announces Investor Call to Provide Corporate Update
  19. Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
  20. DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist